2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
University of Pennsylvania · University of the Witwatersrand · +33 more institutions
Abstract
This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) >10 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation. The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy. Therapeutic decisions are based on the LDL-C level.…
Citation impact
- FWCI
- 95.85
- Percentile
- 100%
- References
- 96
Authors
23Topics & keywords
- Medicine
- Familial hypercholesterolemia
- Genetic testing
- Statement (logic)
- Lipoprotein(a)
- Intensive care medicine
- Family medicine
- Physical therapy
- Good health and well-being
Funding
- AAmgen
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- APAlexion Pharmaceuticals
- MMedpace
- DDanone
- RPRegeneron Pharmaceuticals
- IPIronwood Pharmaceuticals, Incorporated
- UPUltragenyx Pharmaceutical
- RREGENXBIO
- IPIonis Pharmaceuticals
- ACAmarin Corporation
- KCKowa Company
- MMylan
- APAmryt Pharma
- DDaiichi-Sankyo
- APAstellas Pharma
- SServier
- SOSwedish Orphan Biovitrum
- HTHLS Therapeutics
- STSilence Therapeutics
- ETEsperion Therapeutics